Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension : Obesity and heart failure
(2016) In Journal of Hypertension 34(9). p.1678-1688- Abstract
Obese individuals are more likely to develop heart failure. Yet, once heart failure is established, the impact of overweight and obesity on prognosis and survival is unclear. The purpose of this joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension is to provide an overview on the current scientific literature on obesity and heart failure in terms of prognosis, mechanisms, and clinical management implications. Moreover, the document identifies open questions that ought to be addressed. The need for more tailored weight management recommendations in heart failure will be emphasized and, in line with the emerging evidence, aims to distinguish between primary disease and... (More)
Obese individuals are more likely to develop heart failure. Yet, once heart failure is established, the impact of overweight and obesity on prognosis and survival is unclear. The purpose of this joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension is to provide an overview on the current scientific literature on obesity and heart failure in terms of prognosis, mechanisms, and clinical management implications. Moreover, the document identifies open questions that ought to be addressed. The need for more tailored weight management recommendations in heart failure will be emphasized and, in line with the emerging evidence, aims to distinguish between primary disease and secondary outcome prevention. In the primary prevention of heart failure, it appears prudent advising obese individuals to lose or achieve a healthy body weight, especially in those with risk factors such as hypertension or type 2 diabetes. However, there is no evidence from clinical trials to guide weight management in overweight or obese patients with established heart failure. Prospective clinical trials are strongly encouraged.
(Less)
- author
- Jordan, Jens ; Toplak, Hermann ; Grassi, Guido ; Yumuk, Volkan ; Kotsis, Vasilios ; Engeli, Stefan ; Cuspidi, Cesare ; Nilsson, Peter M. LU ; Finer, Nick and Doehner, Wolfram
- organization
- publishing date
- 2016-09-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- heart failure, hypertension, neurohumoral, obesity, obesity paradox
- in
- Journal of Hypertension
- volume
- 34
- issue
- 9
- pages
- 11 pages
- publisher
- Lippincott Williams & Wilkins
- external identifiers
-
- pmid:27488547
- wos:000380870400002
- scopus:84982883832
- ISSN
- 0263-6352
- DOI
- 10.1097/HJH.0000000000001013
- language
- English
- LU publication?
- yes
- id
- 43914174-d228-4573-865d-ae2b4ae6aceb
- date added to LUP
- 2016-09-01 16:28:44
- date last changed
- 2024-01-04 11:54:50
@article{43914174-d228-4573-865d-ae2b4ae6aceb,
abstract = {{<p>Obese individuals are more likely to develop heart failure. Yet, once heart failure is established, the impact of overweight and obesity on prognosis and survival is unclear. The purpose of this joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension is to provide an overview on the current scientific literature on obesity and heart failure in terms of prognosis, mechanisms, and clinical management implications. Moreover, the document identifies open questions that ought to be addressed. The need for more tailored weight management recommendations in heart failure will be emphasized and, in line with the emerging evidence, aims to distinguish between primary disease and secondary outcome prevention. In the primary prevention of heart failure, it appears prudent advising obese individuals to lose or achieve a healthy body weight, especially in those with risk factors such as hypertension or type 2 diabetes. However, there is no evidence from clinical trials to guide weight management in overweight or obese patients with established heart failure. Prospective clinical trials are strongly encouraged.</p>}},
author = {{Jordan, Jens and Toplak, Hermann and Grassi, Guido and Yumuk, Volkan and Kotsis, Vasilios and Engeli, Stefan and Cuspidi, Cesare and Nilsson, Peter M. and Finer, Nick and Doehner, Wolfram}},
issn = {{0263-6352}},
keywords = {{heart failure; hypertension; neurohumoral; obesity; obesity paradox}},
language = {{eng}},
month = {{09}},
number = {{9}},
pages = {{1678--1688}},
publisher = {{Lippincott Williams & Wilkins}},
series = {{Journal of Hypertension}},
title = {{Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension : Obesity and heart failure}},
url = {{http://dx.doi.org/10.1097/HJH.0000000000001013}},
doi = {{10.1097/HJH.0000000000001013}},
volume = {{34}},
year = {{2016}},
}